Arrhythmogenic Cardiomyopathy
DOI:
https://doi.org/10.6016/ZdravVestn.2723Keywords:
Arrhythmogenic Right Ventricular Dysplasia, Ventricular Dysplasia, Cardiomyopathy, ARVD-CAbstract
Arrhythmogenic cardiomyopathy (AC) is a genetic disease of the myocardium characterized by fibro-fatty replacement of the apoptotic myocardium. It primarily affects the right ventricle, however in advanced stages of the disease the left ventricle can also be significantly affected.
AC is a challenging diagnosis, especially in the early stages of the disease, and should be considered in all patients presenting with palpitations, syncope or sudden cardiac death when other, more common causes of these symptoms/signs are excluded. In patients with suspected AC, evaluation according to the current Task Force Criteria should be applied to achieve optimal diagnostic yield.
The main therapeutic concern in AC patients is the prevention of SCD, and thus all patients with established diagnosis have to be evaluated for potential ICD implantation, which is indicated in the majority of symptomatic patients.
In this narrative review we aim to outline current knowledge on the pathophysiology, diagnosis and treatment strategies of AC.
Downloads
References
Corrado D, Thiene G. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: clinical impact of molecular genetic studies. Circulation. 2006 Apr;113(13):1634–7. https://doi.org/10.1161/CIRCULATIONAHA.105.616490 PMID:16585401
Gemayel C, Pelliccia A, Thompson PD. Arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol. 2001 Dec;38(7):1773–81. https://doi.org/10.1016/S0735-1097(01)01654-0PMID:11738273
Basso C, Corrado D, Marcus FI, Nava A, Thiene G. Arrhythmogenic right ventricular cardiomyopathy. Lancet. 2009 Apr;373(9671):1289–300. https://doi.org/10.1016/S0140-6736(09)60256-7 PMID:19362677
Dalal D, Molin LH, Piccini J, Tichnell C, James C, Bomma C, et al. Clinical features of arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in plakophilin-2. Circulation. 2006 Apr;113(13):1641–9. https://doi.org/10.1161/CIRCULATIONAHA.105.568642 PMID:16549640
Maron BJ, Haas TS, Murphy CJ, Ahluwalia A, Rutten-Ramos S. Incidence and causes of sudden death in U.S. college athletes. J Am Coll Cardiol. 2014 Apr;63(16):1636–43. https://doi.org/10.1016/j.jacc.2014.01.041 PMID:24583295
Hoffmayer KS, Scheinman MM. Electrocardiographic patterns of ventricular arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Front Physiol. 2012 Feb;3:23. https://doi.org/10.3389/fphys.2012.00023 PMID:22355290
Rampazzo A, Nava A, Malacrida S, Beffagna G, Bauce B, Rossi V, et al. Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet. 2002 Nov;71(5):1200–6. https://doi.org/10.1086/344208 PMID:12373648
McKoy G, Protonotarios N, Crosby A, Tsatsopoulou A, Anastasakis A, Coonar A, et al. Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet. 2000 Jun;355(9221):2119–24. https://doi.org/10.1016/S0140-6736(00)02379-5 PMID:10902626
te Riele AS, James CA, Groeneweg JA, Sawant AC, Kammers K, Murray B, et al. Approach to family screening in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Eur Heart J. 2016 Mar;37(9):755–63. https://doi.org/10.1093/eurheartj/ehv387 PMID:26314686
Azaouagh A, Churzidse S, Konorza T, Erbel R. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: a review and update. Clin Res Cardiol. 2011 May;100(5):383–94. https://doi.org/10.1007/s00392-011-0295-2 PMID:21360243
Gerull B, Heuser A, Wichter T, Paul M, Basson CT, McDermott DA, et al. Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat Genet. 2004 Nov;36(11):1162–4. https://doi.org/10.1038/ng1461PMID:15489853
Pilichou K, Nava A, Basso C, Beffagna G, Bauce B, Lorenzon A, et al. Mutations in desmoglein-2 gene are associated with arrhythmogenic right ventricular cardiomyopathy. Circulation. 2006 Mar;113(9):1171–9. https://doi.org/10.1161/CIRCULATIONAHA.105.583674 PMID:16505173
Marcus F, Towbin JA, Zareba W, Moss A, Calkins H, Brown M, et al.; ARVD/C Investigators. Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C): a multidisciplinary study: design and protocol. Circulation. 2003 Jun;107(23):2975–8. https://doi.org/10.1161/01.CIR.0000071380.43086.29 PMID:12814984
Marcus FI, Nava A, Thiene G. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: recent advances. Springer Verlag; 2007.
Corrado D, Basso C, Thiene G, McKenna WJ, Davies MJ, Fontaliran F, et al. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol. 1997 Nov;30(6):1512–20. https://doi.org/10.1016/S0735-1097(97)00332-X PMID:9362410
Lopez-Ayala JM, Ortiz-Genga M, Gomez-Milanes I, Lopez-Cuenca D, Ruiz-Espejo F, Sanchez-Munoz JJ, et al. A mutation in the Z-line Cypher/ZASP protein is associated with arrhythmogenic right ventricular cardiomyopathy. Clin Genet. 2015 Aug;88(2):172–6. https://doi.org/10.1111/cge.12458 PMID:25041374
Lin X, Ruiz J, Bajraktari I, Ohman R, Banerjee S, Gribble K, et al. Z-disc-associated, alternatively spliced, PDZ motif-containing protein (ZASP) mutations in the actin-binding domain cause disruption of skeletal muscle actin filaments in myofibrillar myopathy. J Biol Chem. 2014 May;289(19):13615–26. https://doi.org/10.1074/jbc.M114.550418PMID:24668811
Dalal D, Molin LH, Piccini J, Tichnell C, James C, Bomma C, et al. Clinical features of arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in plakophilin-2. Circulation. 2006 Apr;113(13):1641–9. https://doi.org/10.1161/CIRCULATIONAHA.105.568642 PMID:16549640
van Tintelen JP, Entius MM, Bhuiyan ZA, Jongbloed R, Wiesfeld AC, Wilde AA, et al. Plakophilin-2 mutations are the major determinant of familial arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation. 2006 Apr;113(13):1650–8. https://doi.org/10.1161/CIRCULATIONAHA.105.609719 PMID:16567567
Syrris P, Ward D, Asimaki A, Sen-Chowdhry S, Ebrahim HY, Evans A, et al. Clinical expression of plakophilin-2 mutations in familial arrhythmogenic right ventricular cardiomyopathy. Circulation. 2006 Jan;113(3):356–64. https://doi.org/10.1161/CIRCULATIONAHA.105.561654 PMID:16415378
Calabrese F, Basso C, Carturan E, Valente M, Thiene G. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: is there a role for viruses? Cardiovasc Pathol. 2006 Jan-Feb;15(1):11–7. https://doi.org/10.1016/j.carpath.2005.10.004 PMID:16414451
Bowles NE, Ni J, Marcus F, Towbin JA. The detection of cardiotropic viruses in the myocardium of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2002 Mar;39(5):892–5. https://doi.org/10.1016/S0735-1097(02)01688-1PMID:11869858
Mersmann J, Koch A, Tran N, Zimmermann R, Granja TF, Larmann J, et al. Toll-like receptor 2 signaling triggers fatal arrhythmias upon myocardial ischemia-reperfusion. Crit Care Med. 2010 Oct;38(10):1927–32. https://doi.org/10.1097/CCM.0b013e3181ef455bPMID:20855990
Kaplan SR, Gard JJ, Protonotarios N, Tsatsopoulou A, Spiliopoulou C, Anastasakis A, et al. Remodeling of myocyte gap junctions in arrhythmogenic right ventricular cardiomyopathy due to a deletion in plakoglobin (Naxos disease). Heart Rhythm. 2004 May;1(1):3–11. https://doi.org/10.1016/j.hrthm.2004.01.001 PMID:15851108
Kaplan SR, Gard JJ, Carvajal-Huerta L, Ruiz-Cabezas JC, Thiene G, Saffitz JE. Structural and molecular pathology of the heart in Carvajal syndrome. Cardiovasc Pathol. 2004 Jan-Feb;13(1):26–32. https://doi.org/10.1016/S1054-8807(03)00107-8 PMID:14761782
Fontaine G, Frank R, Guiraudon G, et al. Signifi cation des troubles de conduction intraventriculaire observes dans la dysplasie ventriculaire droite arhythmogène. Arc Mal Coeur. 1984;77:872–9.
Basso C, Thiene G, Corrado D, Angelini A, Nava A, Valente M. Arrhythmogenic right ventricular cardiomyopathy. Dysplasia, dystrophy, or myocarditis? Circulation. 1996 Sep;94(5):983–91. https://doi.org/10.1161/01.CIR.94.5.983 PMID:8790036
Thiene G, Basso C. Arrhythmogenic right ventricular cardiomyopathy: an update. Cardiovasc Pathol. 2001 May-Jun;10(3):109–17. https://doi.org/10.1016/S1054-8807(01)00067-9 PMID:11485854
Corrado D, Basso C, Judge DP. Arrhythmogenic Cardiomyopathy. Circ Res. 2017 Sep;121(7):784–802. https://doi.org/10.1161/CIRCRESAHA.117.309345 PMID:28912183
Dalal D, Nasir K, Bomma C, Prakasa K, Tandri H, Piccini J, et al. Arrhythmogenic right ventricular dysplasia: a United States experience. Circulation. 2005 Dec;112(25):3823–32. https://doi.org/10.1161/CIRCULATIONAHA.105.542266 PMID:16344387
Marcus FI, Fontaine GH, Guiraudon G, Frank R, Laurenceau JL, Malergue C, et al. Right ventricular dysplasia: a report of 24 adult cases. Circulation. 1982 Feb;65(2):384–98. https://doi.org/10.1161/01.CIR.65.2.384 PMID:7053899
Nava A, Bauce B, Basso C, Muriago M, Rampazzo A, Villanova C, et al. Clinical profile and long-term follow-up of 37 families with arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol. 2000 Dec;36(7):2226–33. https://doi.org/10.1016/S0735-1097(00)00997-9PMID:11127465
Haugaa KH, Basso C, Badano LP, Bucciarelli-Ducci C, Cardim N, Gaemperli O, et al.; EACVI Scientific Documents Committee, EACVI Board members and external reviewers; EACVI Scientific Documents Committee, EACVI Board members and external reviewers. Comprehensive multi-modality imaging approach in arrhythmogenic cardiomyopathy-an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2017 Mar;18(3):237–53. https://doi.org/10.1093/ehjci/jew229PMID:28069601
McKenna WJ, Thiene G, Nava A, Fontaliran F, Blomstrom-Lundqvist C, Fontaine G, et al.; Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Br Heart J. 1994 Mar;71(3):215–8. https://doi.org/10.1136/hrt.71.3.215 PMID:8142187
Peters S. Advances in the diagnostic management of arrhythmogenic right ventricular dysplasia-cardiomyopathy. Int J Cardiol. 2006 Oct;113(1):4–11. https://doi.org/10.1016/j.ijcard.2005.12.015 PMID:16737750
Femia G, Hsu C, Singarayar S, Sy RW, Kilborn M, Parker G, et al. Impact of new task force criteria in the diagnosis of arrhythmogenic right ventricular cardiomyopathy. Int J Cardiol. 2014 Feb;171(2):179–83. https://doi.org/10.1016/j.ijcard.2013.11.092 PMID:24342399
Kaplan SR, Gard JJ, Protonotarios N, Tsatsopoulou A, Spiliopoulou C, Anastasakis A, et al. Remodeling of myocyte gap junctions in arrhythmogenic right ventricular cardiomyopathy due to a deletion in plakoglobin (Naxos disease). Heart Rhythm. 2004 May;1(1):3–11. https://doi.org/10.1016/j.hrthm.2004.01.001 PMID:15851108
Quarta G, Ward D, Tomé Esteban MT, Pantazis A, Elliott PM, Volpe M, et al. Dynamic electrocardiographic changes in patients with arrhythmogenic right ventricular cardiomyopathy. Heart. 2010 Apr;96(7):516–22. https://doi.org/10.1136/hrt.2009.182949 PMID:20350987
Kazmierczak J, De Sutter J, Tavernier R, Cuvelier C, Dimmer C, Jordaens L. Electrocardiographic and morphometric features in patients with ventricular tachycardia of right ventricular origin. Heart. 1998 Apr;79(4):388–93. https://doi.org/10.1136/hrt.79.4.388PMID:9616349
Marcus FI. Prevalence of T-wave inversion beyond V1 in young normal individuals and usefulness for the diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia. Am J Cardiol. 2005 May;95(9):1070–1. https://doi.org/10.1016/j.amjcard.2004.12.060PMID:15842973
Marcus FI, Zareba W, Calkins H, Towbin JA, Basso C, Bluemke DA, et al. Arrhythmogenic right ventricular cardiomyopathy/dysplasia clinical presentation and diagnostic evaluation: results from the North American Multidisciplinary Study. Heart Rhythm. 2009 Jul;6(7):984–92. https://doi.org/10.1016/j.hrthm.2009.03.013 PMID:19560088
Morin DP, Mauer AC, Gear K, Zareba W, Markowitz SM, Marcus FI, et al. Usefulness of precordial T-wave inversion to distinguish arrhythmogenic right ventricular cardiomyopathy from idiopathic ventricular tachycardia arising from the right ventricular outflow tract. Am J Cardiol. 2010 Jun;105(12):1821–4. https://doi.org/10.1016/j.amjcard.2010.01.365PMID:20538137
Arbelo E, Josephson ME. Ablation of ventricular arrhythmias in arrhythmogenic right ventricular dysplasia. J Cardiovasc Electrophysiol. 2010 Apr;21(4):473–86. https://doi.org/10.1111/j.1540-8167.2009.01694.x PMID:20132399
Hoffmayer KS, Machado ON, Marcus GM, Yang Y, Johnson CJ, Ermakov S, et al. Electrocardiographic comparison of ventricular arrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy and right ventricular outflow tract tachycardia. J Am Coll Cardiol. 2011 Aug;58(8):831–8. https://doi.org/10.1016/j.jacc.2011.05.017 PMID:21835319
Platonov PG, Calkins H, Hauer RN, Corrado D, Svendsen JH, Wichter T, et al. High interobserver variability in the assessment of epsilon waves: implications for diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart Rhythm. 2016 Jan;13(1):208–16. https://doi.org/10.1016/j.hrthm.2015.08.031 PMID:26304715
Marcus FI, Sherrill D. Strengths and weaknesses of the task force criteria: proposed modifications in arrhythmogenic right ventricular cardiomyopathy/dysplasia. In: Marcus FI, Nava A, Thiene G, editors. Arrhythmogenic right ventricular cardiomyopathy dysplasia. Springer; 2007. pp. 97–104.
Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al.; Chamber Quantification Writing Group; American Society of Echocardiography’s Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005 Dec;18(12):1440–63. https://doi.org/10.1016/j.echo.2005.10.005 PMID:16376782
Yoerger DM, Marcus F, Sherrill D, Calkins H, Towbin JA, Zareba W, et al.; Multidisciplinary Study of Right Ventricular Dysplasia Investigators. Echocardiographic findings in patients meeting task force criteria for arrhythmogenic right ventricular dysplasia: new insights from the multidisciplinary study of right ventricular dysplasia. J Am Coll Cardiol. 2005 Mar;45(6):860–5. https://doi.org/10.1016/j.jacc.2004.10.070 PMID:15766820
Sen-Chowdhry S, Prasad SK, Syrris P, Wage R, Ward D, Merrifield R, et al. Cardiovascular magnetic resonance in arrhythmogenic right ventricular cardiomyopathy revisited: comparison with task force criteria and genotype. J Am Coll Cardiol. 2006 Nov;48(10):2132–40. https://doi.org/10.1016/j.jacc.2006.07.045 PMID:17113003
Saberniak J, Leren IS, Haland TF, Beitnes JO, Hopp E, Borgquist R, et al. Comparison of patients with early-phase arrhythmogenic right ventricular cardiomyopathy and right ventricular outflow tract ventricular tachycardia. Eur Heart J Cardiovasc Imaging. 2017 Jan;18(1):62–9. https://doi.org/10.1093/ehjci/jew014 PMID:26903598
Tandri H, Saranathan M, Rodriguez ER, Martinez C, Bomma C, Nasir K, et al. Noninvasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed-enhancement magnetic resonance imaging. J Am Coll Cardiol. 2005 Jan;45(1):98–103. https://doi.org/10.1016/j.jacc.2004.09.053 PMID:15629382
Etoom Y, Govindapillai S, Hamilton R, Manlhiot C, Yoo SJ, Farhan M, et al. Importance of CMR within the Task Force Criteria for the diagnosis of ARVC in children and adolescents. J Am Coll Cardiol. 2015 Mar;65(10):987–95. https://doi.org/10.1016/j.jacc.2014.12.041PMID:25766945
Keller DI, Osswald S, Bremerich J, Bongartz G, Cron TA, Hilti P, et al. Arrhythmogenic right ventricular cardiomyopathy: diagnostic and prognostic value of the cardiac MRI in relation to arrhythmia-free survival. Int J Cardiovasc Imaging. 2003 Dec;19(6):537–43. https://doi.org/10.1023/B:CAIM.0000004351.40409.ee PMID:14690194
Prati G, Vitrella G, Allocca G, Muser D, Buttignoni SC, Piccoli G, et al. Right Ventricular Strain and Dyssynchrony Assessment in Arrhythmogenic Right Ventricular Cardiomyopathy: Cardiac Magnetic Resonance Feature-Tracking Study. Circ Cardiovasc Imaging. 2015 Nov;8(11):e003647. https://doi.org/10.1161/CIRCIMAGING.115.003647 PMID:26534932
Sen-Chowdhry S, Morgan RD, Chambers JC, McKenna WJ. Arrhythmogenic cardiomyopathy: etiology, diagnosis, and treatment. Annu Rev Med. 2010;61(1):233–53. https://doi.org/10.1146/annurev.med.052208.130419 PMID:20059337
Ackerman M, Priori S, Willems S, Berul C, Brugada R et. al. HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies: This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA), 2011; vol: 13 (8) pp: 1077-1109
Pinamonti B, Brun F, Mestroni L, Sinagra G. Arrhythmogenic right ventricular cardiomyopathy: from genetics to diagnostic and therapeutic challenges. World J Cardiol. 2014 Dec;6(12):1234–44. https://doi.org/10.4330/wjc.v6.i12.1234 PMID:25548613
Johnson CJ, Roberts JD, James JH, Hoffmayer KS, Badhwar N, Ku IA, et al. Comparison of radionuclide angiographic synchrony analysis to echocardiography and magnetic resonance imaging for the diagnosis of arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm. 2015 Jun;12(6):1268–75. https://doi.org/10.1016/j.hrthm.2015.02.033 PMID:25744613
Munkholm J, Andersen CB, Ottesen GL. Plakoglobin: a diagnostic marker of arrhythmogenic right ventricular cardiomyopathy in forensic pathology? Forensic Sci Med Pathol. 2015 Mar;11(1):47–52. https://doi.org/10.1007/s12024-014-9644-6 PMID:25549959
Aquaro GD, Pingitore A, Strata E, Di Bella G, Molinaro S, Lombardi M. Cardiac magnetic resonance predicts outcome in patients with premature ventricular complexes of left bundle branch block morphology. J Am Coll Cardiol. 2010 Oct;56(15):1235–43. https://doi.org/10.1016/j.jacc.2010.03.087 PMID:20883930
Steckman DA, Schneider PM, Schuller JL, Aleong RG, Nguyen DT, Sinagra G, et al. Utility of cardiac magnetic resonance imaging to differentiate cardiac sarcoidosis from arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol. 2012 Aug;110(4):575–9. https://doi.org/10.1016/j.amjcard.2012.04.029 PMID:22595349
Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014 Feb;63(4):329–36. https://doi.org/10.1016/j.jacc.2013.09.022 PMID:24140661
La Gerche A, Claessen G, Van de Bruaene A, Pattyn N, Van Cleemput J, Gewillig M, et al. Cardiac MRI: a new gold standard for ventricular volume quantification during high-intensity exercise. Circ Cardiovasc Imaging. 2013 Mar;6(2):329–38. https://doi.org/10.1161/CIRCIMAGING.112.980037 PMID:23258478
Galderisi M, Cardim N, D’Andrea A, Bruder O, Cosyns B, Davin L, et al. The multi-modality cardiac imaging approach to the Athlete’s heart: an expert consensus of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015 Apr;16(4):353–353r. https://doi.org/10.1093/ehjci/jeu323 PMID:25681828
Oxborough D, Sharma S, Shave R, Whyte G, Birch K, Artis N, et al. The right ventricle of the endurance athlete: the relationship between morphology and deformation. J Am Soc Echocardiogr. 2012 Mar;25(3):263–71. https://doi.org/10.1016/j.echo.2011.11.017PMID:22172988
Judge DP. Use of genetics in the clinical evaluation of cardiomyopathy. JAMA. 2009 Dec;302(22):2471–6. https://doi.org/10.1001/jama.2009.1787 PMID:19996403
Corrado D, Wichter T, Link MS, Hauer R, Marchlinski F, Anastasakis A, et al. Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement. Eur Heart J. 2015 Dec;36(46):3227–37. PMID:26216920
Lemola K, Brunckhorst C, Helfenstein U, Oechslin E, Jenni R, Duru F. Predictors of adverse outcome in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy: long term experience of a tertiary care centre. Heart. 2005 Sep;91(9):1167–72. https://doi.org/10.1136/hrt.2004.038620 PMID:16103549
Turrini P, Corrado D, Basso C, Nava A, Bauce B, Thiene G. Dispersion of ventricular depolarization-repolarization: a noninvasive marker for risk stratification in arrhythmogenic right ventricular cardiomyopathy. Circulation. 2001 Jun;103(25):3075–80. https://doi.org/10.1161/01.CIR.103.25.3075 PMID:11425771
Corrado D, Leoni L, Link MS, Della Bella P, Gaita F, Curnis A, et al. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation. 2003 Dec;108(25):3084–91. https://doi.org/10.1161/01.CIR.0000103130.33451.D2 PMID:14638546
Hulot JS, Jouven X, Empana JP, Frank R, Fontaine G. Natural history and risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation. 2004 Oct;110(14):1879–84. https://doi.org/10.1161/01.CIR.0000143375.93288.82 PMID:15451782
Pinamonti B, Dragos AM, Pyxaras SA, Merlo M, Pivetta A, Barbati G, et al. Prognostic predictors in arrhythmogenic right ventricular cardiomyopathy: results from a 10-year registry. Eur Heart J. 2011 May;32(9):1105–13. https://doi.org/10.1093/eurheartj/ehr040PMID:21362707
Hong TT, Cogswell R, James CA, Kang G, Pullinger CR, Malloy MJ, et al. Plasma BIN1 correlates with heart failure and predicts arrhythmia in patients with arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm. 2012 Jun;9(6):961–7. https://doi.org/10.1016/j.hrthm.2012.01.024 PMID:22300662
Baumwart RD, Orvalho J, Meurs KM. Evaluation of serum cardiac troponin I concentration in Boxers with arrhythmogenic right ventricular cardiomyopathy. Am J Vet Res. 2007 May;68(5):524–8. https://doi.org/10.2460/ajvr.68.5.524 PMID:17472453
Saberniak J, Hasselberg NE, Borgquist R, Platonov PG, Sarvari SI, Smith HJ, et al. Vigorous physical activity impairs myocardial function in patients with arrhythmogenic right ventricular cardiomyopathy and in mutation positive family members. Eur J Heart Fail. 2014 Dec;16(12):1337–44. https://doi.org/10.1002/ejhf.181 PMID:25319773
Corrado D, Basso C, Rizzoli G, Schiavon M, Thiene G. Does sports activity enhance the risk of sudden death in adolescents and young adults? J Am Coll Cardiol. 2003 Dec;42(11):1959–63. https://doi.org/10.1016/j.jacc.2003.03.002 PMID:14662259
James CA, Bhonsale A, Tichnell C, Murray B, Russell SD, Tandri H, et al. Exercise increases age-related penetrance and arrhythmic risk in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol. 2013 Oct;62(14):1290–7. https://doi.org/10.1016/j.jacc.2013.06.033 PMID:23871885
Wichter T, Borggrefe M, Haverkamp W, Chen X, Breithardt G. Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia. Circulation. 1992 Jul;86(1):29–37. https://doi.org/10.1161/01.CIR.86.1.29 PMID:1617780
Marcus GM, Glidden DV, Polonsky B, Zareba W, Smith LM, Cannom DS, et al.; Multidisciplinary Study of Right Ventricular Dysplasia Investigators. Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry. J Am Coll Cardiol. 2009 Aug;54(7):609–15. https://doi.org/10.1016/j.jacc.2009.04.052 PMID:19660690
Wichter T, Borggrefe M, Haverkamp W, Chen X, Breithardt G. Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia. Circulation. 1992 Jul;86(1):29–37. https://doi.org/10.1161/01.CIR.86.1.29 PMID:1617780
Wichter T, Paul TM, Eckardt L, Gerdes P, Kirchhof P, Böcker D, et al. Arrhythmogenic right ventricular cardiomyopathy. Antiarrhythmic drugs, catheter ablation, or ICD? Herz. 2005 Mar;30(2):91–101. https://doi.org/10.1007/s00059-005-2677-6 PMID:15875097
Ponikowski P, Voors A, Anker S, Bueno H, Cleland J et. al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2016; vol: 37 (27) pp: 2129-2200
Wlodarska EK, Wozniak O, Konka M, Rydlewska-Sadowska W, Biederman A, Hoffman P. Thromboembolic complications in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. Europace. 2006 Aug;8(8):596–600. https://doi.org/10.1093/europace/eul053 PMID:16760233
Jánosi A, Vágó H, Hubay M. [Arrhytmogenic right ventricle—prognostic significance of exercise test]. Orv Hetil. 2010 Dec;151(52):2145–9. https://doi.org/10.1556/OH.2010.28995PMID:21147700
Corrado D, Leoni L, Link MS, Della Bella P, Gaita F, Curnis A, et al. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation. 2003 Dec;108(25):3084–91. https://doi.org/10.1161/01.CIR.0000103130.33451.D2 PMID:14638546
Corrado D, Calkins H, Link MS, Leoni L, Favale S, Bevilacqua M, et al. Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia. Circulation. 2010 Sep;122(12):1144–52. https://doi.org/10.1161/CIRCULATIONAHA.109.913871 PMID:20823389
Bhonsale A, James CA, Tichnell C, Murray B, Gagarin D, Philips B, et al. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. J Am Coll Cardiol. 2011 Sep;58(14):1485–96. https://doi.org/10.1016/j.jacc.2011.06.043 PMID:21939834
Wichter T, Paul M, Wollmann C, Acil T, Gerdes P, Ashraf O, et al. Implantable cardioverter/defibrillator therapy in arrhythmogenic right ventricular cardiomyopathy: single-center experience of long-term follow-up and complications in 60 patients. Circulation. 2004 Mar;109(12):1503–8. https://doi.org/10.1161/01.CIR.0000121738.88273.43 PMID:15007002
Boriani G, Artale P, Biffi M, Martignani C, Frabetti L, Valzania C, et al. Outcome of cardioverter-defibrillator implant in patients with arrhythmogenic right ventricular cardiomyopathy. Heart Vessels. 2007 May;22(3):184–92. https://doi.org/10.1007/s00380-006-0963-8 PMID:17533523
Breithardt G, Wichter T, Haverkamp W, Borggrefe M, Block M, Hammel D, et al. Implantable cardioverter defibrillator therapy in patients with arrhythmogenic right ventricular cardiomyopathy, long QT syndrome, or no structural heart disease. Am Heart J. 1994 Apr;127(4 Pt 2):1151–8. https://doi.org/10.1016/0002-8703(94)90103-1 PMID:8160595
Hodgkinson KA, Parfrey PS, Bassett AS, Kupprion C, Drenckhahn J, Norman MW, et al. The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrhythmogenic right ventricular cardiomyopathy (ARVD5). J Am Coll Cardiol. 2005 Feb;45(3):400–8. https://doi.org/10.1016/j.jacc.2004.08.068 PMID:15680719
Piccini JP, Dalal D, Roguin A, Bomma C, Cheng A, Prakasa K, et al. Predictors of appropriate implantable defibrillator therapies in patients with arrhythmogenic right ventricular dysplasia. Heart Rhythm. 2005 Nov;2(11):1188–94. https://doi.org/10.1016/j.hrthm.2005.08.022 PMID:16253908
Roguin A, Bomma CS, Nasir K, Tandri H, Tichnell C, James C, et al. Implantable cardioverter-defibrillators in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2004 May;43(10):1843–52. https://doi.org/10.1016/j.jacc.2004.01.030 PMID:15145110
Schuler PK, Haegeli LM, Saguner AM, Wolber T, Tanner FC, Jenni R, et al. Predictors of appropriate ICD therapy in patients with arrhythmogenic right ventricular cardiomyopathy: long term experience of a tertiary care center. PLoS One. 2012;7(9):e39584. https://doi.org/10.1371/journal.pone.0039584 PMID:23028419
Tavernier R, Gevaert S, De Sutter J, De Clercq A, Rottiers H, Jordaens L, et al. Long term results of cardioverter-defibrillator implantation in patients with right ventricular dysplasia and malignant ventricular tachyarrhythmias. Heart. 2001 Jan;85(1):53–6. https://doi.org/10.1136/heart.85.1.53 PMID:11119463
Link MS, Wang PJ, Haugh CJ, Homoud MK, Foote CB, Costeas XB, et al. Arrhythmogenic right ventricular dysplasia: clinical results with implantable cardioverter defibrillators. J Interv Card Electrophysiol. 1997 Feb;1(1):41–8. https://doi.org/10.1023/A:1009714718034PMID:9869950
Ingles J, Sarina T, Kasparian N, Semsarian C. Psychological wellbeing and posttraumatic stress associated with implantable cardioverter defibrillator therapy in young adults with genetic heart disease. Int J Cardiol. 2013 Oct;168(4):3779–84. https://doi.org/10.1016/j.ijcard.2013.06.006 PMID:23835269
Moss AJ, Schuger C, Beck CA, Brown MW, Cannom DS, Daubert JP, et al.; MADIT-RIT Trial Investigators. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med. 2012 Dec;367(24):2275–83. https://doi.org/10.1056/NEJMoa1211107 PMID:23131066
Basso C, Corrado D, Marcus FI, Nava A, Thiene G. Arrhythmogenic right ventricular cardiomyopathy. Lancet. 2009 Apr;373(9671):1289–300. https://doi.org/10.1016/S0140-6736(09)60256-7 PMID:19362677
Dalal D, Jain R, Tandri H, Dong J, Eid SM, Prakasa K, et al. Long-term efficacy of catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2007 Jul;50(5):432–40. https://doi.org/10.1016/j.jacc.2007.03.049 PMID:17662396
Corrado D, Leoni L, Link MS, Della Bella P, Gaita F, Curnis A, et al. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation. 2003 Dec;108(25):3084–91. https://doi.org/10.1161/01.CIR.0000103130.33451.D2 PMID:14638546
Published
Issue
Section
License
The Author transfers to the Publisher (Slovenian Medical Association) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Slovenian Medical Association) has the right to transfer the rights of acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
